Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report
Diagnostics · 19.11.2026 · 16 (22) · 3879
DOI: 10.3390/diagnostics16223879 ↗Kurz gefasst
Fallbericht in der Zeitschrift Diagnostics, online erschienen am 19.11.2026. Verfasst von Ji Yeon Min und 2 weiteren Autor:innen. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background and Clinical Significance: Atypical hemolytic uremic syndrome (aHUS) is a rare, life-threatening, complement-mediated thrombotic microangiopathy (TMA) that may occur de novo after kidney transplantation. Because its manifestations overlap with more common causes of allograft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection, diagnosis can be challenging. The disease may progress rapidly, making early clinical suspicion and timely etiologic evaluation essential. Case Presentation: We report a 52-year-old man who developed abrupt, severe graft dysfunction approximately 10 years after ABO-incompatible living-donor kidney transplantation. His serum creatinine had remained approximately 2.0 mg/dL after treatment for suspected chronic active antibody-mediated rejection but increased to 6.57 mg/dL at outpatient follow-up and to 8.47 mg/dL on admission after a recent norovirus infection. Initial evaluation considered common post-transplant causes of graft dysfunction, including rejection, calcineurin inhibitor toxicity, and infection-related injury. However, as renal dysfunction progressed and concurrent anemia and thrombocytopenia became evident, TMA was suspected, and a targeted workup was undertaken. Elevated lactate dehydrogenase, decreased haptoglobin, fragmented red blood cells, and allograft biopsy findings supported TMA. No HLA class I or II antibodies were detected, C4d staining was negative, ADAMTS13 activity was preserved, and testing for Shiga toxin-producing Escherichia coli was negative. Genetic testing identified a heterozygous CFH variant (c.3329G>C, p.Gly1110Ala), classified as a variant of uncertain significance. Based on the clinical, hematologic, and histopathologic findings, suspected aHUS was considered the most likely diagnosis. However, ABMR-associated TMA could not be completely excluded. Plasma exchange was complicated by anaphylaxis, and eculizumab was initiated. Hematologic abnormalities subsequently resolved, although renal function did not recover and the patient remained dialysis-dependent. Conclusions: This case highlights the importance of considering TMA when graft dysfunction progresses rapidly or remains unexplained, even many years after kidney transplantation. Early recognition of microangiopathic features and prompt evaluation for the underlying etiology are particularly important when complement-mediated aHUS is suspected, because established acute-on-chronic allograft injury may limit renal recovery despite hematologic response to C5 inhibition.
Zitieren
APA
Min, J. Y., Jang, Y. J., & Kim, H. S. (2026). Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report. Diagnostics, 16(22), 3879. https://doi.org/10.3390/diagnostics16223879
Vancouver
Min JY, Jang YJ, Kim HS. Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report. Diagnostics. 2026;16(22):3879. doi:10.3390/diagnostics16223879
BibTeX
@article{Min2026,
author = {Min, Ji Yeon and Jang, Young Joo and Kim, Hyo Sang},
title = {Eculizumab Therapy in Suspected Late-Onset Atypical Hemolytic Uremic Syndrome in an Adult Kidney Transplant Recipient: A Case Report},
journal = {Diagnostics},
year = {2026},
volume = {16},
number = {22},
pages = {3879},
doi = {10.3390/diagnostics16223879}
}
EUVIMED